- Home
- DSM vs NTHI Comparison
DSM vs NTHI Comparison
Compare DSM & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSM | NTHI |
|---|---|---|
| Founded | 1989 | 2008 |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 243.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DSM | NTHI |
|---|---|---|
| Price | $6.25 | $8.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 81.3K | 61.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.28 | $3.20 |
| 52 Week High | $6.30 | $16.00 |
Technical Indicators
Market Signals| Indicator | DSM | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 60.59 | 44.47 |
| Support Level | $6.21 | $9.05 |
| Resistance Level | $6.23 | $11.38 |
| Average True Range (ATR) | 0.05 | 1.17 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 82.35 | 7.26 |
Price Performance
Historical ComparisonAbout DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).